Retatrutide, Triple-Agonist for Weight Loss, Awaits FDA Review | Retatrutide News
Retatrutide, a triple-agonist drug for weight loss, is under FDA review. Eli Lilly is developing it as part of their metabolic pipeline.
Market News · October 23, 2026
Retatrutide, a triple-agonist drug for weight loss, is under FDA review. Eli Lilly is developing it as part of their metabolic pipeline.
Market News · October 23, 2026